If you have been reading about thymosin alpha 1 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-13. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
==== Torture and executions ==== The use of sulfur has been reported in some Early Modern executions by burning. In 1553, in Geneva, Spanish theologian Michael Servetus was condemned to be burned at the stake for heresy, wearing a wreath of straw and leaves sprayed with sulfur. In France, some of the people convicted of offenses punishable by burning were given a sulfur shirt ("chemise soufrée") to wear at the stake. This kind of garment has been mentioned in convictions for witchcraft, as with Urbain Grandier in 1634, and convictions for homosexuality, as with Jean Diot and Bruno Lenoir in 1750. Sulfur was also part of the French punishment for regicide. The hand that held the assassination weapon would be scorched with flaming sulfur; the body of the culprit would be torn with pincers, and the wounds covered with molten lead, boiling oil, pitch, hot resin, wax and sulfur, before being quartered by horses. Such was the fate of Ravaillac for murdering Henry IV of France in 1610, and of Robert-François Damiens for his failed assassination attempt targeting Louis XV in 1757. A sulfur-based torture device was used in 18th century Brittany by the local authorities. "Escarpins soufrés" or "chaussons soufrés" (meaning "sulfured slippers") were a pair of shoes, usually made of leather, smeared with sulfur to burn the victim's feet during interrogation.
Documents seized during the 2011 operation that killed bin Laden included notes handwritten by bin Laden in September 2002 with the heading "The Birth of the Idea of September 11." He describes how he was inspired by the crash of EgyptAir Flight 990 in October 1999, which was deliberately crashed by co-pilot Gameel Al-Batouti, killing more than 200 passengers. "This is how the idea of 9/11 was conceived and developed in my head, and that is when we began the planning" bin Laden continued, adding that no one but Mohammed Atef and Abu al-Khair knew about it at the time. The 9/11 Commission Report identified Khalid Sheikh Mohammed as the architect of 9/11, but he is not mentioned in bin Laden's notes.
In development, the viability of the process on a semi-commercial scale has to be demonstrated. Trial quantities of the new fine chemical have to be manufactured for market development, clinical tests, and other requirements. The necessary data has to be generated in order to enable the engineering department to plan the modifications of the industrial-scale plant and in order to calculate production costs for the expected large-volume requirements. Both equipment and plant layout of the pilot plant reflect those of an industrial multipurpose plant, except for the size of reaction vessels (bench-scale laboratory ~10–60 liters; pilot plant ~100–2500 liters) and the degree of process automation. Before the process is ready for transfer to the industrial-scale plant, the following activities have to be completed: adaptation of the laboratory process to the constraints of a pilot plant, hazard and operability (HAZOP) analysis, and execution of demonstration batches. The main differences between laboratory synthesis and industrial scale production are shown in Table 4.
Meprobamate, sold under the brand names Miltown and Equanil, among others, is a carbamate derivative used as an anxiolytic drug. It was the best-selling minor tranquilizer for a time, but has largely been replaced by the benzodiazepines due to their wider therapeutic index (lower risk of toxicity at therapeutically prescribed doses) and lower incidence of serious side effects.
Scientists at the company argued for developing a companion diagnostic and limiting testing of the drug only to patients with biomarkers showing they were likely to respond, and received agreement from management. Some people, including shareholders and analysts, criticized this decision as it limited the potential market size for the drug, while others argued it increased the chances of proving the drug would work and would make clinical trials faster. (The trials would need fewer participants because of the likelihood of greater effect size.) Moving quickly and reducing the risk of failure was essential for catching up with Bristol-Myers Squibb, which had an approximate five year lead over Merck. The phase I study started in early 2011, and Eric Rubin, who was running the melanoma trial, argued for and was able to win expansion of the trial until it reached around 1300 people. This was the largest phase I study ever run in oncology, with the participants roughly divided between melanoma and lung cancer. In 2013, Merck quietly applied for and won a breakthrough therapy designation for the drug. This regulatory pathway was new at the time and not well understood. One of its advantages is that the US FDA holds more frequent meetings with drug developers, reducing the risk of developers of making mistakes or misunderstandings arising from the differences between regulators' expectations and what the developers want to do.
Sources: en.wikipedia.org
==== Employee opposition to AI militarisation ==== In May 2026, workers at Google DeepMind's London headquarters voted to unionise, requesting joint representation by the Communication Workers Union (CWU) and Unite the Union. The unionisation drive was heavily motivated by ethical concerns regarding Google's military-industrial AI contracts, specifically the provision of AI technology to the US Department of Defense and the Israeli military.
In India, the profession of clinical psychology is regulated by the Rehabilitation Council of India (RCI), a statutory body under the Ministry of Social Justice and Empowerment. The RCI is responsible for standardizing training curricula, recognizing institutions, and maintaining the Central Rehabilitation Register (CRR) of licensed professionals. Registration with the RCI is mandatory to practice legally as a clinical psychologist and to issue official certificates of mental illness. The primary pathway to becoming an RCI-licensed clinical psychologist is through completing a specialized postgraduate program followed by RCI registration. A significant reform is underway, with the traditional M.Phil. in Clinical Psychology (a two-year program) being phased out and replaced by a new M.A. in Clinical Psychology program, in alignment with the National Education Policy (NEP) 2020. The 2025–26 academic year is expected to be the final intake for the M.Phil. program. Other RCI-recognized professional programs include the Doctor of Psychology (Psy.D.) and the Professional Diploma in Clinical Psychology (PDCP).
It develops most often only after prolonged (months, years or even decades) exposure to antidopaminergics. Extrapyramidal side effects. Motor symptoms such as tremor, parkinsonism, involuntary movements, reduced ability to move one's voluntary muscles, etc. Unknown incidence or relationship to drug treatment adverse effects include:
In 2010, McGregor was appointed by the French government as a Chevalier de l'Ordre des Arts et Lettres (Knight of the Order of the Arts and Letters). McGregor was appointed an Officer of the Order of the British Empire (OBE) in the 2013 New Year Honours for services to drama and charity.
Sources: en.wikipedia.org
Australia, Hong Kong, Israel, Macau and South Korea do not stamp passports upon entry nor exit. These countries or regions issue landing slips instead, except for Australia, which does not issue any physical evidence of entry. Visas may also take the form of passport stamps. Immigration authorities usually use different stamp styles for entries and exits to make it easier to track people's movements. Ink colour might be used to designate the mode of transportation (air, land, or sea), as in Hong Kong before 1997, while border styles did the same in Macau. Other variations include changing the stamp size to indicate the length of stay, as in Singapore. In many cases, passengers on cruise ships do not receive passport stamps because the entire vessel has been cleared into port. It is often possible to get a souvenir stamp, although this requires finding the immigration office by the dock. In many cases, officials are used to such requests and will cooperate. Also, as noted below, some of the smallest European countries will give a stamp on request, either at their border or tourist office charging, at most, a nominal fee.
Surface-supplied diving equipment (SSDE) is the equipment required for surface-supplied diving. The essential aspect of surface-supplied diving is that breathing gas is supplied from the surface, either from a specialised diving compressor, high-pressure gas storage cylinders, or both. In commercial and military surface-supplied diving, a backup source of surface-supplied breathing gas should always be present in case the primary supply fails. The diver may also wear a bailout cylinder (emergency gas supply) which can provide self-contained breathing gas in an emergency. Thus, the surface-supplied diver is less likely to have an "out-of-air" emergency than a scuba diver using a single gas supply, as there are normally two alternative breathing gas sources available. Surface-supplied diving equipment usually includes communication capability with the surface, which improves the safety and efficiency of the working diver. The equipment needed for surface supplied diving can be broadly grouped as diving and support equipment, but the distinction is not always clear. Diving support equipment is equipment used to facilitate a diving operation. It is either not taken into the water during the dive, such as the gas panel and compressor, or is not integral to the actual diving, being there to make the dive easier or safer, such as a surface decompression chamber. Some equipment, like a diving stage, is not easily categorised as diving or support equipment, and may be considered as either.
=== Biological strategies === It has become possible to accelerate natural aerobic, anaerobic, and sequential aerobic and/or anaerobic biological processes to minimize the presence of NAPLs in the subsurface environment. Most bioremediation strategies rely on the presence of specific populations of bacteria/microorganisms and the addition of organic carbon to stimulate biodegradation. This organic carbon can be supplied via injection of soluble organic carbon sources such as lactate, alcohols, cheese whey, etc. and placement of slow-release electron donors such as vegetable oil and soybean oil emulsions. Sufficient dissolved oxygen must be present for aerobic biodegradation, which can be supplied through strategies including air sparging and SVE. That said, the ability to supply sufficient oxygen is a limiting factor affecting the success of this type of remediation strategy. Also, many cases require the presence of inducers such as methane, propane, ammonia, or toluene, which are contaminants in and of themselves that are inherently harmful to the subsurface environment. Yet another challenge is maintaining a sufficient population of bacteria/microorganisms in the face of competition from native bacteria and other external pressures. There is also regulatory pushback to the use of genetically modified bacteria. Furthermore, NAPLs may not be readily bioavailable, limiting the effectiveness of biodegradation strategies. In this sense, biodegradation may not be appropriate as a single solution, but it can certainly be used in conjunction with other strategies.
== Areas == In-space manufacturing (ISM) can be categorized into three different areas according to the end use of manufactured products. In-space manufacturing for space (space-for-space) involves activities focused on in-orbit construction intended for use in space. ISM for Earth (space-for-Earth) is the production of new materials and products that exhibit enhanced properties when manufactured in microgravity, subsequently transported back to Earth. Lastly, ISM for surface extends to surface operations on celestial bodies such as the Moon, Mars, and asteroids.
Although the European Union does not have a codified constitution, like every political body it has laws which "constitute" its basic governance structure. The EU's primary constitutional sources are the Treaty on European Union and the Treaty on the Functioning of the European Union, which have been agreed or adhered to among the governments of all 27 member states. The Treaties establish the EU's institutions, list their powers and responsibilities, and explain the areas in which the EU can legislate with Directives or Regulations. In 1983, the European Court of Justice has referred to the Treaties as being a "basic constitutional charter" for the first time. The European Commission has the right to propose new laws, formally called the right of legislative initiative. During the ordinary legislative procedure, the Council (whose members are ministers from member state governments) and the European Parliament (elected by citizens) can make amendments and must give their consent for laws to pass. The Commission oversees departments and various agencies that execute or enforce EU law. The "European Council" (rather than the Council of the European Union, made up of different government Ministers) is composed of the Prime Ministers or executive presidents of the member states. It appoints the Commissioners and the board of the European Central Bank. The European Court of Justice is the supreme judicial body which interprets EU law, and develops it through precedent. The Court can review the legality of the EU institutions' actions, in compliance with the Treaties.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.